Travere Financial Statements From 2010 to 2026

Stocks . USA . 
Stock . Travere Therapeutics
TVTX Stock  USD 29.75  0.41  1.40%   
Travere Therapeutics' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Travere Therapeutics' valuation are provided below:
Gross Profit
274.4 M
Profit Margin
(0.05)
Market Capitalization
2.8 B
Enterprise Value Revenue
6.4854
Revenue
490.7 M
We have found one hundred twenty available fundamental trend indicators for Travere Therapeutics, which can be analyzed and compared to other ratios and to its competition. All investors should make sure to double-check all of Travere Therapeutics current market performance against the performance between 2010 and 2026 to make sure the company can sustain itself down the road. Market Cap is likely to rise to about 3.6 B in 2026. Enterprise Value is likely to rise to about 3.8 B in 2026

Travere Therapeutics Total Revenue

515.26 Million

Check Travere Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Travere Therapeutics' main balance sheet or income statement drivers, such as Interest Expense of 14.8 M, Selling General Administrative of 318.9 M or Other Operating Expenses of 581.2 M, as well as many indicators such as Price To Sales Ratio of 5.81, Dividend Yield of 0.0 or PTB Ratio of 31.17. Travere financial statements analysis is a perfect complement when working with Travere Therapeutics Valuation or Volatility modules.
  
Build AI portfolio with Travere Stock
Check out the analysis of Travere Therapeutics Correlation against competitors.
For more information on how to buy Travere Stock please use our How to Invest in Travere Therapeutics guide.

Travere Therapeutics Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets486.4 M605.2 M444.8 M
Slightly volatile
Short and Long Term Debt Total183.7 M328.7 M168 M
Slightly volatile
Other Current Liabilities75 M129.2 M68.5 M
Slightly volatile
Total Current Liabilities103.2 M159.9 M94.4 M
Slightly volatile
Accounts Payable14.7 M24.8 M13.5 M
Slightly volatile
Cash61.2 M93 M55.9 M
Slightly volatile
Cash And Short Term Investments296.7 M322.8 M271.3 M
Slightly volatile
Common Stock Total Equity3.5 K6.9 K3.6 K
Slightly volatile
Common Stock Shares Outstanding51.3 M89.2 M46.9 M
Slightly volatile
Liabilities And Stockholders Equity486.4 M605.2 M444.8 M
Slightly volatile
Non Current Liabilities Total224.4 M330.5 M205.2 M
Slightly volatile
Other Stockholder Equity1.7 B1.6 B689.4 M
Slightly volatile
Total Liabilities327.5 M490.4 M299.4 M
Slightly volatile
Total Current Assets335.5 M437.6 M306.8 M
Slightly volatile
Short Term Debt5.6 M5.9 M13.8 M
Pretty Stable
Common Stock10.9 K10.3 K4.7 K
Slightly volatile
Property Plant And Equipment Net12.1 M14.6 M9.8 M
Slightly volatile
Non Current Assets Total172.5 M167.6 M139.5 M
Slightly volatile
Other Current Assets30.2 M28.8 M9.5 M
Slightly volatile
Intangible Assets133.5 M113.9 M108.1 M
Slightly volatile
Short Term Investments289.8 M229.8 M218.6 M
Slightly volatile
Property Plant And Equipment Gross34.3 M32.6 M12.6 M
Slightly volatile
Net Receivables84.1 M80.1 M28.8 M
Slightly volatile
Good Will709.7 K677.7 K875.8 K
Slightly volatile
Inventory5.9 M5.9 M4.3 M
Slightly volatile
Other Liabilities67.7 M76.1 M88 M
Slightly volatile
Long Term Debt268.1 M356.9 M170 M
Slightly volatile
Net Invested Capital507.4 M503.8 M415.8 M
Slightly volatile
Non Current Liabilities Other5.8 M6.1 M68 M
Slightly volatile
Net Working Capital376.8 M248.3 M296.9 M
Slightly volatile
Property Plant Equipment11.8 M10.4 M7.5 M
Slightly volatile
Short and Long Term Debt50.1 M79 M43.7 M
Slightly volatile
Capital Stock6.4 K10.3 K5.3 K
Slightly volatile
Long Term Debt Total172.3 M193.8 M211.5 M
Slightly volatile
Capital Surpluse1.1 B1.2 B901.1 M
Slightly volatile
Capital Lease Obligations23.4 M20.3 M28 M
Slightly volatile

Travere Therapeutics Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Interest Expense14.8 M10.7 M13.5 M
Very volatile
Selling General Administrative318.9 M303.7 M131.3 M
Slightly volatile
Other Operating Expenses581.2 M553.6 M266 M
Slightly volatile
Total Operating Expenses262.2 M482.5 M239.8 M
Slightly volatile
Depreciation And Amortization63.8 M60.7 M21 M
Slightly volatile
Research Development142.5 M206 M115.1 M
Slightly volatile
Total Revenue515.3 M490.7 M158.4 M
Slightly volatile
Gross Profit440.6 M419.6 M146.5 M
Slightly volatile
Cost Of Revenue74.6 M71.1 M12 M
Slightly volatile
Reconciled Depreciation30.7 M50.1 M25.2 M
Slightly volatile
Interest Income10.8 M20.5 M8.4 M
Slightly volatile
Non Recurring77.7 M87.4 M95.4 M
Slightly volatile
Selling And Marketing Expenses30.1 M33.9 M37 M
Slightly volatile

Travere Therapeutics Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Begin Period Cash Flow54.8 M58.5 M50.1 M
Slightly volatile
Depreciation63.8 M60.7 M21 M
Slightly volatile
End Period Cash Flow61.2 M93 M55.9 M
Slightly volatile
Stock Based Compensation29.5 M44.9 M25.9 M
Slightly volatile
Dividends Paid75 M84.3 M92 M
Slightly volatile
Change To Netincome43.7 M37.4 M47.4 M
Very volatile
Issuance Of Capital Stock112.3 M121.3 M132.4 M
Very volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio5.816.94648.0266
Slightly volatile
Days Sales Outstanding84.0159.603183.0873
Slightly volatile
Average Payables3.1 M4.8 M4.5 M
Slightly volatile
Stock Based Compensation To Revenue0.08690.09140.2967
Slightly volatile
Capex To Depreciation4.352.674.5596
Slightly volatile
EV To Sales6.667.42679.3683
Slightly volatile
Inventory Turnover12.712.09912.2427
Slightly volatile
Days Of Inventory On Hand28.6630.1676395
Slightly volatile
Payables Turnover3.012.86620.5863
Slightly volatile
Sales General And Administrative To Revenue0.881.021.3206
Slightly volatile
Average Inventory827.4 K1.5 M1.2 M
Slightly volatile
Research And Ddevelopement To Revenue0.820.41981.1751
Slightly volatile
Capex To Revenue0.410.390.2193
Slightly volatile
Cash Per Share4.213.61835.1965
Slightly volatile
Days Payables Outstanding1211272.1 K
Slightly volatile
Intangibles To Total Assets0.180.18820.4051
Slightly volatile
Current Ratio1.982.73642.5952
Slightly volatile
Receivables Turnover5.466.12385.9743
Slightly volatile
Capex Per Share1.581.482.5947
Slightly volatile
Average Receivables31.8 M30.3 M24.6 M
Slightly volatile
Revenue Per Share5.785.50072.8649
Slightly volatile
Interest Debt Per Share3.043.80533.753
Slightly volatile
Debt To Assets0.520.54320.7877
Slightly volatile
Graham Number21.2123.8626.0385
Slightly volatile
Operating Cycle85.2889.7707477
Slightly volatile
Days Of Payables Outstanding1211272.1 K
Slightly volatile
Long Term Debt To Capitalization1.140.73762.4883
Slightly volatile
Quick Ratio1.962.69972.562
Slightly volatile
Net Income Per E B T1.01.02010.9324
Slightly volatile
Cash Ratio0.380.58180.5021
Slightly volatile
Days Of Inventory Outstanding28.6630.1676395
Slightly volatile
Days Of Sales Outstanding84.0159.603183.0873
Slightly volatile
Fixed Asset Turnover48.133.616143.5877
Slightly volatile
Debt Ratio0.520.54320.7877
Slightly volatile
Price Sales Ratio5.816.94648.0266
Slightly volatile
Asset Turnover0.850.81090.3062
Slightly volatile
Gross Profit Margin1.060.85510.9682
Pretty Stable

Travere Therapeutics Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap3.6 B3.4 B1.1 B
Slightly volatile
Enterprise Value3.8 B3.6 B1.2 B
Slightly volatile

Travere Fundamental Market Drivers

Forward Price Earnings19.7628
Cash And Short Term Investments322.8 M

Travere Upcoming Events

22nd of February 2024
Upcoming Quarterly Report
View
2nd of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
22nd of February 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Travere Therapeutics Financial Statements

Travere Therapeutics investors use historical fundamental indicators, such as Travere Therapeutics' revenue or net income, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Travere Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue2.5 M2.4 M
Total Revenue490.7 M515.3 M
Cost Of Revenue71.1 M74.6 M
Stock Based Compensation To Revenue 0.09  0.09 
Sales General And Administrative To Revenue 1.02  0.88 
Research And Ddevelopement To Revenue 0.42  0.82 
Capex To Revenue 0.39  0.41 
Revenue Per Share 5.50  5.78 
Ebit Per Revenue(0.13)(0.13)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
FSLYFastly Class A
MOBMobilicom Limited American
CMGChipotle Mexican Grill

Additional Tools for Travere Stock Analysis

When running Travere Therapeutics' price analysis, check to measure Travere Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Travere Therapeutics is operating at the current time. Most of Travere Therapeutics' value examination focuses on studying past and present price action to predict the probability of Travere Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Travere Therapeutics' price. Additionally, you may evaluate how the addition of Travere Therapeutics to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY